Jump to section
To power critical decisions in health care with data science-driven technology.
Aetion provides real-world evidence (RWE), predictive analytics, and healthcare modeling based on real-world data (RWD) to drug companies, payers, life science companies, and regulatory agencies. Its evidence platform is trusted by top global biopharma firms, leading payers, and regulatory bodies to evaluate the safety, effectiveness, and value of medical products.
Since its founding, Aetion has conducted over 9,000 treatment effectiveness analyses and has become integral to the US Food and Drug Administration's modern drug approval and safety processes. With the growing demand for evidence-based solutions in healthcare becoming especially evident in recent years.
Aetion is expanding its platform capabilities, increasing its presence in Europe and the Asia-Pacific region, and strengthening its commercial team. With key partnerships and acquisitions, the company is well-positioned to lead in healthcare development as more health-related data becomes available through devices and wearables.
Freddie
Company Specialist at Welcome to the Jungle
May 2021
$110m
SERIES C
Aug 2020
$19m
SERIES B
Jeremy Rassen
(Co-Founder & CEO)An epidemiologist and computer scientist with nearly 25 years of experience in the science and technology of big data. Prior to Aetion, was Assistant Professor of Medicine at Harvard Medical School, and has worked a number of Silicon Valley jobs with Hewlitt-Packard and Epiphany.
Operations & Strategy
Finance, Legal & Compliance